Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5462 in Stable Patients With Chronic Heart Failure
NCT06299826Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of AZD5462 in chronic heart failure (CHF), sponsored by AstraZeneca. Started Jun 2024; status: completed.
02
Drugs
AZD5462
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06299826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299826.